San Francisco will allow alcoholic drinks to-go in part of The Castro during certain events
The Castro District is the latest San Francisco neighborhood that will get to have open-container alcoholic drinks on some of its streets during certain events.
In a unanimous vote, the San Francisco Board of Supervisors established the Castro Upper Market Entertainment Zone.
The Entertainment Zone will mostly encompass 14th Street to Collingwood Street on Market Street, on Castro Street from States Street to 19th Street, and on 18th Street from Collingwood Street to Sanchez Street.
"The Entertainment Zone should be a significant benefit for neighborhood bars and restaurants, especially during Night Market events and this fall at the Castro Street Fair," said Board President Rafael Mandelman in a press release. "Now more than ever we need to support our local businesses and show the world that our gayborhood remains the best in the world."
Entertainment Zones allow for bars, restaurants, wineries and breweries to sell alcoholic drinks to-go. The drinks are allowed only in the confines of the entertainment zone and is only permitted during Entertainment Zone events.
The drinks will have to be in compostable or reusable containers.
The Castro Upper Market zone will be the city's fourth. The others are on
Front Street, at Thrive City
and
at Cole Valley.
San Francisco Mayor Daniel Lurie has pushed for the creation of more Entertainment Zones. In early April,
he announced legislation
for five new zones.
The Entertainment Zones have been credited with providing big boosts in sales for businesses. In a previous release, the mayor's office said businesses reported an increase in sales of at least 700%.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Deep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final Perspectives on Why Change is Needed in the Boardroom
Deep Track's Nominees Are Prepared to Collectively Enter the Boardroom with Open-Minded Perspectives, Constructive Approach and Sole Focus on Creating Value for All Shareholders Believes that Without Meaningful Board Change "Valid and Critical Questions Regarding Dynavax's Strategic Direction, Capital Allocation, and Board Responsiveness" Will Remain Unanswered Details Urgent Need to Address Company's Consistent Failure to Achieve Stated Targets and Reverse Heplisav Market Share Stagnation GREENWICH, Conn., June 09, 2025--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, "Deep Track" or "we"), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) ("Dynavax", "DVAX" or the "Company"), with ownership of approximately 14.82% of the Company's outstanding shares, today issued a letter to shareholders detailing the benefits of electing Deep Track's four nominees – Brett Erkman, Jeffrey Farrow, Michael Mullette and Donald Santel – to the Board of Directors (the "Board") at the upcoming 2025 Annual Meeting of Shareholders (the "Annual Meeting") on June 11, 2025. For more information, including details on how to vote Deep Track's WHITE proxy card, please visit The full text of the letter follows: Dear Fellow Dynavax shareholders, We would like to express our appreciation for the opportunity we have had over the course of this campaign to engage with so many of you. Deep Track undertook this effort because, as one of Dynavax's largest and longest-tenured shareholders, we believe deeply in the Company and its value creation potential. With the Annual Meeting now only a few days away, we want to convey a few final thoughts about why we believe new, independent and fully objective perspectives should be added to the Board. First, the numbers speak for themselves. The key asset at Dynavax is Heplisav, but under the Board's increasing pressure for inorganic growth, Heplisav is not reaching its full potential. As outlined in the Company's proxy statement1, Heplisav failed to achieve both key metrics established by the Board: 2024 Board Target 2024 Result Outcome Heplisav U.S. sales $275 million $268 million Missed by $7 million U.S. market share in 4Q 47% 44% Missed by 3 p.p. Management cautions that market share numbers should only be evaluated on a year-over-year basis and dismisses the slip to 43% market share in the first quarter of 2025. But even through that lens the numbers are troubling: fourth quarter market share in 2023 was 42%2, which means there were only two percentage points of growth in 2024 – a substantial decline from the seven points achieved in the year prior. At this rate, Heplisav will fall far short of the Company's 60% target for 2030 – yet management contended on the earnings call last month that this is "exactly how we had planned."3 Shares fell 11% the next day.4 We believe that growing questions about Heplisav growth with a distracted management team combined with an outsized cash pile with no coherent strategy for deployment have taken their toll on the share price. While the Company points to a "pivot" in 2019 when it made the unsurprising choice to focus on its only approved product, this reference point ignores the multi-year losses since then – both on an absolute basis and against the Company's benchmark historically used in its own proxy filings5, the Nasdaq Biotechnology Index (NBI): DVAX NBI DVAX vs. NBI One year -17% -6% -10% Two years -12% +2% -14% Three years -15% +17% -32% Slowing market share growth, missed revenue targets, and a stock price meaningfully underperforming the Company's index for years all point to fundamental problems at Dynavax – problems that are a direct result of the questionable Board strategy of diversifying the Company away from its lead asset. Second, without new voices in the boardroom, nothing will change. As leading proxy advisory firm Glass, Lewis & Co. ("Glass Lewis") noted in its report,6 our campaign "…highlighted valid and critical questions regarding Dynavax's strategic direction, capital allocation, and board responsiveness." By voting for the incumbent directors up for election, you would be voting to leave these questions unaddressed and effectively assenting to the current strategy set by Chairman Scott Myers without any further debate, assessment, or new thinking. As Glass Lewis wrote when recommending against Mr. Myers, shareholders would be "best served" by electing Deep Track directors who would bring "relevant and differentiated perspectives to the Board." Shareholders must also keep in mind that a "wait and see" approach simply will not work. Due to the Board's imbalanced class of directors and the classified structure not ending until 2028, there is only one independent director up for election next year – making this year's Annual Meeting a uniquely important opportunity to effect real change.7 Finally, the truth about Deep Track and our nominees. The current Board has made repeated and increasingly baseless mischaracterizations regarding Deep Track, our nominees and our campaign. Consider these facts: Our director nominees are open-minded and ready to work constructively to do what is best for all Dynavax shareholders. Suggesting that highly respected and experienced professionals like our nominees would violate their fiduciary duties is nothing more than campaign theatre. The Company has particularly targeted Deep Track principal Brett Erkman, accusing him of being "rigid" in his views. In fact, all evidence points to the contrary: in the years of engagement Brett has had with Dynavax and the communications over the course of this campaign (including the very last settlement offer he proposed to Ryan Spencer on April 17, 2025, which the Board flatly rejected over a week later with no substantive dialogue in the interim), Brett consistently and explicitly made clear that he was always "open to discussion" and "happy to engage" on any point of potentially differing opinions, including specifics on capital allocation, board composition and the components of the two-year standstill. Deep Track is one of Dynavax's largest and longest-tenured investors – the antithesis of "short-term." Our principals first invested in Dynavax a decade before any incumbent director up for election this year had joined the Board. The idea that we are looking for a quick profit at the expense of the Company's best interests is simply false. We also do not understand how the Board can believe a single shareholder representative could engineer such an outcome; again, this is more theatre that defies logic and yet another attempt to distract from the facts. Deep Track is not a typical "activist" – this is the first time we have publicly engaged at all with a portfolio company, much less run a proxy contest. Our nominees would bring needed valuable experience, independence and investor perspective to the Dynavax Board. Throughout this campaign, we have struggled to understand why Dynavax has fought so hard (while spending shareholder capital) to prevent a nearly 15% shareholder from having a representative on the Board. Regardless of these motivations, the reality is that our directors are needed. As Glass Lewis concluded in its report, "...we find that the board is notably lacking in directors with direct capital markets or institutional investor backgrounds," and specifically regarding Brett, "Mr. Erkman's extensive background as a public equity investor in the life sciences sector addresses what we believe is a notable deficiency in the current board's composition and could help sharpen the board's approach to capital allocation, shareholder engagement, and long-term value creation." We appreciate you taking the time to consider our views. We truly believe that by voting for all four Deep Track nominees, you can help to unlock the value that Dynavax can deliver and put the Company on a better path to success. For more information, including details on how to vote Deep Track's WHITE proxy card, please visit Regards, David KroinFounder and Chief Investment Officer, Deep Track Capital LP EVERY VOTE MATTERS Your vote is important, no matter how many shares of Common Stock you own. If you have any questions, require assistance in voting your WHITE proxy card, or need additional copies of Deep Track's proxy materials, please visit or contact our proxy solicitor, Innisfree M&A Incorporated ("Innisfree"), using the contact information provided here: Innisfree M&A Incorporated501 Madison Avenue, 20th FloorNew York, New York 10022Stockholders call toll-free (877) 687-1865 About Deep Track Capital Deep Track Capital is a Greenwich, Connecticut-based investment firm focused exclusively on the life sciences industry. We develop long term partnerships with management teams of leading innovative public and pre-IPO biotechnology companies. In addition to capital, we seek to invest our time and expertise, while leveraging our network for the benefit of our partners. We aim to lead transactions while building large syndicates, and also to invest in rounds led by other qualified investors. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS The information herein contains "forward-looking statements." Specific forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and include, without limitation, words such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "potential," "targets," "forecasts," "seeks," "could," "should" or the negative of such terms or other variations on such terms or comparable terminology. Similarly, statements that describe our objectives, plans or goals are forward-looking. Forward-looking statements are subject to various risks and uncertainties and assumptions. There can be no assurance that any idea or assumption herein is, or will be proven, correct. If one or more of the risks or uncertainties materialize, or if any of the underlying assumptions of Deep Track Capital, LP ("Deep Track") or any of the other participants in the proxy solicitation described herein prove to be incorrect, the actual results may vary materially from outcomes indicated by these statements. Accordingly, forward looking statements should not be regarded as a representation by Deep Track that the future plans, estimates or expectations contemplated will ever be achieved. Certain statements and information included herein may have been sourced from third parties. Deep Track does not make any representations regarding the accuracy, completeness or timeliness of such third party statements or information. Except as may be expressly set forth herein, permission to cite such statements or information has neither been sought nor obtained from such third parties. Any such statements or information should not be viewed as an indication of support from such third parties for the views expressed herein. Deep Track disclaims any obligation to update the information herein or to disclose the results of any revisions that may be made to any projected results or forward-looking statements herein to reflect events or circumstances after the date of such information, projected results or statements or to reflect the occurrence of anticipated or unanticipated events. CERTAIN INFORMATION CONCERNING THE PARTICIPANTS Deep Track and the other Participants (as defined below) have filed a definitive proxy statement and accompanying WHITE universal proxy card with the Securities and Exchange Commission (the "SEC") to be used to solicit proxies for, among other matters, the election of its slate of director nominees at the 2025 annual stockholders meeting (the "2025 Annual Meeting") of Dynavax Technologies Corporation, a Delaware corporation ("DVAX"). Shortly after filing its definitive proxy statement with the SEC, Deep Track furnished the definitive proxy statement and accompanying WHITE universal proxy card to some or all of the stockholders entitled to vote at the 2025 Annual Meeting. The participants in the proxy solicitation are Deep Track, Deep Track Biotechnology Master Fund, Ltd. (the "Record Stockholder"), David Kroin (all of the foregoing persons, collectively, the "Deep Track Parties"), Brett A. Erkman, Jeffrey S. Farrow, Michael Mullette and Donald J. Santel (such individuals, collectively with the Deep Track Parties, the "Participants"). As of the date hereof, the Deep Track Parties beneficially own an aggregate of 17,791,486 shares (the "Deep Track Shares") of the common stock, par value $0.001 per share, of DVAX (the "Common Stock"). The Deep Track Shares collectively represent approximately 14.53% of the outstanding shares of Common Stock based on 122,411,685 shares of Common Stock outstanding as of the record date for the 2025 Annual Meeting as reported in DVAX's Definitive Proxy Statement filed with the SEC on April 17, 2025. Each of the Deep Track Parties may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) all of the Deep Track Shares. As of the date hereof, none of the other Participants beneficially own any shares of Common Stock. IMPORTANT INFORMATION AND WHERE TO FIND IT DEEP TRACK STRONGLY ADVISES ALL STOCKHOLDERS OF DVAX TO READ THE DEFINITIVE PROXY STATEMENT, ANY AMENDMENTS OR SUPPLEMENTS TO SUCH PROXY STATEMENT, AND OTHER PROXY MATERIALS FILED BY DEEP TRACK WITH THE SEC BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC'S WEBSITE AT THE DEFINITIVE PROXY STATEMENT, WHEN FILED, AND OTHER RELEVANT DOCUMENTS, WILL ALSO BE AVAILABLE BY DIRECTING A REQUEST TO THE PARTICIPANTS' PROXY SOLICITOR, INNISFREE M&A INCORPORATED, 501 MADISON AVENUE, 20th FLOOR, NEW YORK, NY 10022 (STOCKHOLDERS CAN CALL TOLL-FREE: (877)-687-1865). __________________________ 1 Dynavax definitive proxy statement filed April 17, 2025. 2 Dynavax 4Q23 earnings call, recorded Feb 22, 2024. 3 Dynavax 1Q25 earnings call recorded May 6, 2025. 4 Share price calculated market close May 6, 2025 through market close May 7, 2025. 5 Dynavax definitive proxy statement filed April 11, 2024. 6 Permission to quote Glass Lewis was neither sought nor received. 7 Dynavax 2025 proxy statement filed April 17, 2025, identifies Daniel L. Kisner (independent) and Ryan Spencer (CEO) as the only Class II directors continuing in office until the 2026 annual meeting. View source version on Contacts Investor Contact Innisfree M&A IncorporatedScott Winter / Gabrielle Wolf+1 212-750-5833 Media Contact Longacre Square Partnersdeeptrack@
Yahoo
5 hours ago
- Yahoo
Burcon Achieves First Commercial Production of Pea Protein
Vancouver, British Columbia--(Newsfile Corp. - June 9, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein innovation, is pleased to announce the successful first commercial production run of its next-generation Peazazz®C pea protein at its Galesburg facility in Illinois, USA. "The successful startup of our Galesburg facility marks a key operational milestone in Burcon's commercial scale-up," said Kip Underwood, Burcon's chief executive officer. "In less than 90 days since commissioning, our team has brought next-generation protein production online, enabling us to meet accelerating customer demand and unlock scalable revenue opportunities." Burcon remains on track to achieve key operational and financial milestones through 2025/2026. The Company anticipates the following revenue targets: $1-3 million in revenue for calendar year 2025 $10+ million in revenue for calendar year 2026 Positive cash flow projected to be achieved in calendar year 2026 With commercial production now underway and ramping through the second half of 2025, Burcon is actively progressing customer supply agreements that will support long-term recurring revenue. The Galesburg facility provides meaningful capacity to scale production and positions the Company to execute its growth plan, expand market penetration, and drive long-term enterprise value. Share Consolidation Burcon announces it has consolidated its issued and outstanding common shares (the "Shares") at a ratio of twenty (20) pre-consolidation Shares to one (1) post-consolidation share (the "Consolidation"). The Shares are expected to commence trading on the TSX on a post-Consolidation basis at the start of trading on June 11, 2025. The Company's name and trading symbol will remain the same after the Consolidation. Peter H. Kappel, Burcon's Chairman of the board commented: "We are confidently advancing our strategic plan, and the Consolidation marks a key step in optimizing our capital structure and unlocking long-term value for shareholders. This initiative is designed to attract new investors, improve the marketability of our common shares, and position Burcon for future growth." The Consolidation has been approved by the board of directors of Burcon (the "Board") and by shareholders of the Company (the "Shareholders") pursuant to the share consolidation authorizing resolution approved at the Company's most recent annual general and special meeting of Shareholders held on September 18, 2024. As discussed in greater detail in the management information circular of the Company dated August 1, 2024, the Board believes that implementing the Consolidation is in the best interests of the Company as it could lead to increased interest by a wider audience of potential investors and result in less volatility resulting in a more efficient market for the Common Shares. The Board also regularly evaluates other opportunities to increase the Company's access to capital markets and the Consolidation could allow the Company to access other exchanges that have minimum listing requirements. No fractional Shares will be issued under the Consolidation. The holdings of any Shareholder who would otherwise be entitled to receive a fractional Share as a result of the Consolidation shall be rounded up to the next higher whole number if the fraction is 0.5 or greater and rounded down to the next lower whole number if the fraction is less than 0.5. The Consolidation will not affect any Shareholder's percentage ownership in the Company other than by the minimal effect of the aforementioned elimination of fractional Shares, even though such ownership will be represented by a smaller number of Shares. Instead, the Consolidation will reduce proportionately the number of Shares held by all Shareholders. There were 253,761,444 common shares of Burcon outstanding prior to the Consolidation. Shareholders who hold uncertificated Shares (including Shares held through a brokerage account and/or not represented by a physical share certificate), will have their holdings electronically adjusted by the Company's transfer agent or by their brokerage firms, banks, trust or other nominees. Such Shareholders do not need to take any additional actions to exchange their pre-Consolidation Shares for post-Consolidation Shares. Letters of transmittal are being mailed to all registered Shareholders holding share certificates with instructions on how to exchange existing share certificate(s) for new share certificate(s). A copy of the letter of transmittal will also be available on the Company's profile on SEDAR+. The Company's new CUSIP number for the post-Consolidation Shares will be 120831300 and its new ISIN number is CA1208313009. The exercise price and number of Common Shares issuable upon the exercise of Burcon's outstanding warrants will be proportionately adjusted to reflect the Consolidation in accordance with the terms of such securities. About Burcon NutraScience Corporation Burcon is a global technology leader in high-performance plant-based proteins for the food and beverage industry. Our commercial ingredients offer superior taste, texture, and functionality-ideal for formulators seeking next-generation protein solutions. Backed by over two decades of innovation, Burcon holds an extensive patent portfolio covering novel proteins derived from pea, canola, soy, hemp, sunflower, and other plant sources. As a key player in the rapidly growing plant-based market, Burcon is committed to sustainability and to creating best-in-class protein solutions that are better for people and the planet. Learn more at Forward-Looking Information Cautionary Statement The TSX has not reviewed and does not accept responsibility for the adequacy of the content of the information contained herein. This press release contains forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements or forward-looking information involve risks, uncertainties and other factors that could cause actual results, performances, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements or forward-looking information can be identified by words such as "anticipate," "aim", "intend," "plan," "goal," "project," "estimate," "expect," "believe," "future," "likely," "may," "should," "could," "will" and similar references to future periods. All statements included in this release, other than statements of historical fact, are forward-looking statements. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements or information. Important factors that could cause actual results to differ materially from Burcon's plans and expectations include the implementation of our business model and growth strategies; trends and competition in our industry our future business development, financial condition and results of operations and our ability to obtain financing cost-effectively; potential changes of government regulations, and other risks and factors detailed herein and from time to time in the filings made by Burcon with securities regulators and stock exchanges, including in the section entitled "Risk Factors" in Burcon's annual information form for the year ended March 31, 2024 and its other public filings with Canadian securities regulators on SEDAR+ at This list is not exhaustive of the factors that may affect any of the Company's forward-looking statements or information. Any forward-looking statement or information speaks only as of the date on which it was made, and, except as may be required by applicable securities laws, Burcon disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Although Burcon believes the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance, and, accordingly, investors should not rely on such statements. Industry and Investor ContactPaul LamDirector, Investor Relations and CommunicationsBurcon NutraScience Corporation490 - 999 West Broadway, Vancouver, BC, V5Z 1K5Tel (604) 733-0896, Toll-free (888) 408-7960plam@ Media Contact:Steve Campbell, APRPresidentCampbell & Company Public RelationsTel (604) 888-5267TECH@ To view the source version of this press release, please visit
Yahoo
5 hours ago
- Yahoo
Ceres Global Ag Corp. Announces Filing of Circular and Receipt of Interim Order in Relation to Proposed Plan of Arrangement with Bartlett Grain Company
MINNEAPOLIS, June 9, 2025 /CNW/ - Ceres Global Ag Corp. ("Ceres" or the "Corporation") (TSX: CRP) today announced that it has filed and is in the process of mailing its management information circular (the "Circular") and related materials to shareholders of Ceres (the "Shareholders") in connection with the special meeting (the "Meeting") of Shareholders to be held on Monday, June 30, 2025, to consider and vote on a special resolution (the "Arrangement Resolution") approving the previously announced statutory plan of arrangement pursuant to which 1001239530 Ontario Inc., a newly formed entity controlled by Bartlett Grain Company, LLC, will acquire all of the issued and outstanding common shares of Ceres (the "Shares") for a price of US$4.50 per Share, in cash (the "Transaction"), all as more particularly described in the Circular. The Circular and related materials can be accessed on Ceres' website at as well as under Ceres' profile on SEDAR+ at Shareholders are urged to carefully review and consider the Circular and related materials, which contain important information concerning the Transaction and the rights and entitlements of the Shareholders in relation thereto and to consult with their financial, tax, legal or other professional advisors. Voting at Virtual Meeting of Shareholders The Meeting will be held virtually on June 30, 2025 at 8:30 a.m. EST. Shareholders can access the Meeting using the following link: (case sensitive password: ceres2025). The Circular provides important and detailed instructions about how to participate in the Meeting. Only registered Shareholders as at the close of business on May 30, 2025 (or their duly appointed and registered proxyholders), are entitled to receive notice of and to vote at the Meeting. The deadline for completed proxies to be received by the Corporation's transfer agent, TSX Trust Company, is Thursday, June 26, 2025 at 8:30 a.m. EST (or, if the Meeting is adjourned or postponed, no later than forty-eight (48) hours (excluding Saturdays, Sundays and statutory holidays in Ontario) before the adjourned meeting is reconvened or the postponed meeting is convened). Shareholders are encouraged to cast their votes well in advance of the proxy voting deadline. Receipt of Interim Court Order On May 28, 2025, the Ontario Superior Court of Justice (Commercial List) (the "Court") granted an interim order in respect of the Transaction (the "Interim Order"). The Interim Order authorizes Ceres to proceed with various matters relating to the Transaction, including the holding of the Meeting for Shareholders to consider and vote on the Arrangement Resolution. Recommendation of the Independent Committee and the Board The Board's standing independent committee (the "Independent Committee"), after receiving financial advice from Blair Franklin Capital Partners Inc., an independent financial advisor retained by the Board, unanimously recommended that the Board approve the Transaction and recommend that Shareholders vote in favour of the Arrangement Resolution at the Meeting. The Board, after receiving advice from its independent financial advisor and outside legal counsel and the unanimous recommendation of the Independent Committee, unanimously determined that the Transaction is in the best interests of the Corporation and is fair to Shareholders and unanimously recommends that Shareholders vote in favour of the Arrangement Resolution. About Ceres Global Ag Corp. Ceres and its subsidiaries add value across agricultural, energy and industrial supply chains through efficient sourcing, storing, transporting and marketing of high‐quality agricultural commodities, value‐added products and raw materials. Leveraging its network of commodity logistics centers and team of industry experts, Ceres connects farmers to customers around the world. Ceres is headquartered in Golden Valley, Minnesota, and together with its affiliated companies, operates 10 locations across Saskatchewan, Manitoba, and Minnesota. These facilities have an aggregate grain and oilseed storage capacity of approximately 29 million bushels. The Corporation also owns membership interests in three agricultural joint ventures that have an aggregate grain and oilseed storage capacity of approximately 16 million bushels. Ceres has a 50% interest in Savage Riverport, LLC (a joint venture with Consolidated Grain and Barge Co.), a 50% interest in Berthold Farmers Elevator, LLC (a joint venture with The Berthold Farmers Elevator Company), a 50% interest in Farmers Grain, LLC (a joint venture with Farmer's Cooperative Grain and Seed Association), a 41.6% interest in Gateway Energy Terminal (an unincorporated joint venture with Steel Reef Infrastructure Corp.), and a 25% interest in Stewart Southern Railway Inc. (a short‐line railway located in southeast Saskatchewan with a range of 130 kilometers). For more information about Ceres, please visit Forward-Looking Information This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation and United States securities laws. Forward-looking information may include, but is not limited to, statements regarding the Transaction, the timing of the Meeting and the mailing date of the Meeting materials. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", "believes", "may have implications" or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might", or "will be taken", "occur", or "be achieved". Forward-looking information is based on the opinions and estimates of management at the date the information is made and is based on a number of assumptions and subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Key assumptions upon which such forward-looking information is based are listed in the "Key Assumptions & Advisories" section of the MD&A for the period ended March 31, 2025. Many such assumptions are based on factors and events that are not within the control of Ceres and there is no assurance they will prove to be correct. The risks and uncertainties the forward looking information is subject to include, but are not limited to, the risk factors described in greater detail under "Risk Factors" of the Circular relating to the Meeting. These risks and uncertainties further include (but are not limited to), as concerns the Transaction, the failure of the parties to obtain the necessary Shareholder, regulatory and Court approvals or to otherwise satisfy the conditions to the completion of the Transaction, failure of the parties to obtain such approvals or satisfy such conditions in a timely manner, significant Transaction costs or unknown liabilities, failure to realize the expected benefits of the Transaction, and general economic conditions. Failure to obtain the necessary Shareholder, regulatory and Court approvals, or the failure of the parties to otherwise satisfy the conditions to the completion of the Transaction or to complete the Transaction, may result in the Transaction not being completed on the proposed terms, or at all. In addition, if the Transaction is not completed, and the Corporation continues as a publicly-traded entity, there are risks that the announcement of the proposed Transaction and the dedication of substantial resources of the Corporation to the completion of the Transaction could have an impact on its business and strategic relationships (including with future and prospective employees, customers, suppliers and partners), operating results and activities in general, and could have a material adverse effect on its current and future operations, financial condition and prospects. Factors that could cause actual results to vary materially from results anticipated by such forward-looking information include, among others, risks related to weather, politics and governments, changes in environmental and other laws and regulations, competitive factors in agricultural, food processing and feed sectors, construction and completion of capital projects, labour, equipment and material costs, access to capital markets, interest and currency exchange rates, technological developments, global and local economic conditions, the ability of Ceres to successfully implement strategic initiatives and whether such strategic initiatives will yield the expected benefits, the operating performance of the Corporation's assets, the availability and price of commodities and regulatory environment, processes and decisions. Although Ceres has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results that are not anticipated, estimated or intended. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Ceres undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change, except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking information. SOURCE Ceres Global Ag Corp. View original content:
